As EGFR and MET pathways are common pathways of resistance [147,148], one notable combination involves amivantamab with TKIs in advanced NSCLC patients harboring ALK, ROS1, and RET gene fusions. The gene discussed is ALK; the disease is non-small cell lung carcinoma.